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Introduction: Over the years the prevalence of metabolic syndrome (MetS) has
drastically increased in developing countries as a major byproduct of industrialization.
Many factors, such as the consumption of high-calorie diets and a sedentary lifestyle,
bolster the spread of this disorder. Undoubtedly, themassive and still increasing incidence
of MetS places this epidemic as an important public health issue. Hereon we revisit
another outlook of MetS beyond its classical association with cardiovascular disease
(CVD) and Diabetes Mellitus Type 2 (DM2), for MetS also poses a risk factor for the
nervous tissue and threatens neuronal function. First, we revise a few essential concepts
of MetS pathophysiology. Second, we explore some neuroprotective approaches in MetS
pertaining brain hypoxia. The articles chosen for this review range from the years 1989
until 2017; the selection criteria was based on those providing data and exploratory
information on MetS as well as those that studied innovative therapeutic approaches.
Pathophysiology: The characteristically impaired metabolic pathways of MetS lead to
hyperglycemia, insulin resistance (IR), inflammation, and hypoxia, all closely associated
with an overall pro-oxidative status. Oxidative stress is well-known to cause the wreckage
of cellular structures and tissue architecture. Alteration of the redox homeostasis and
oxidative stress alter the macromolecular array of DNA, lipids, and proteins, in turn
disrupting the biochemical pathways necessary for normal cell function.
Neuroprotection: Different neuroprotective strategies are discussed involving lifestyle
changes, medication aimed to mitigate MetS cardinal symptoms, and treatments
targeted toward reducing oxidative stress. It is well-known that the routine practice
of physical exercise, aerobic activity in particular, and a complete and well-balanced
nutrition are key factors to prevent MetS. Nevertheless, pharmacological control of MetS
as a whole and pertaining hypertension, dyslipidemia, and endothelial injury contribute
to neuronal health improvement.
Conclusion: The development of MetS has risen as a risk factor for neurological
disorders. The therapeutic strategies include multidisciplinary approaches directed to
address different pathological pathways all in concert.
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INTRODUCTION
Definition
Metabolic syndrome (MetS) is a disorder characterized by a
cluster of conditions that increases the risk of developing
cardiovascular disease (CVD) and Type 2 Diabetes Mellitus
(DM2) (International Diabetes Federation, 2006). Currently,
there are still controversies among the different Health
Organizations on the selection criteria for this syndrome. The
most accepted diagnostic tool is the global consensus described
by the International Diabetes Federation (IDF) (International
Diabetes Federation, 2006) that entails the presence of:
• Central obesity (based on waist circumference): ≥80 cm for
women and ≥90 cm for men from the Hispanic background
(values vary with ethnicity).
• Plus two or more of the following parameters:
1. Hypertriglyceridemia: ≥ 150 mg/dL, or under treatment for
this lipid abnormality.
2. HDL-cholesterolemia below recommendations: <40 mg/dL
in men and <50 mg/dL in women, or history of specific
treatment for this lipid abnormality.
3. Hypertension: SBP ≥ 130 mmHg and/or DBP ≥ 85 mmHg
over 24 h.
4. Fasting Hyperglycemia: ≥100 mg/dL, hyperinsulinemia, or
DM2.
Metabolic syndrome (MetS) has been associated with hepatic
steatosis, respiratory illness, osteoarticular disease, and cancer
(Siegel and Zhu, 2009). The main mechanism implicated in
the pathogenesis of MetS is the resistance to insulin (IR),
namely the insufficient response to physiological insulin levels
(Eckel, 2005). Other aspects that can shape MetS pathology
are environmental stressors, mostly chemical, infections, lifestyle
(sedentary habits, smoking, and nutritional factors), genetic
predisposition, and other chronic diseases. These characteristics
have one common denominator which is the generalized pro-
oxidative status, in turn favoring free radical generation and
resulting in oxidative stress (Roberts and Sindhu, 2009). The
specificmetabolic pathways typically affected by the development
of MetS are discussed in more detail later in this work.
Epidemiology
Metabolic syndrome (MetS) affects nearly 30% of the world
population, associated with a 2–3-fold increase in morbidity
and mortality compared with healthy people (Engin, 2017).
In regard to the global statistics of MetS, an important item
to highlight is the lack of unanimity on the diagnosis of this
syndrome, specifically derived from the regional variation of
the cut-off values for waist circumference linked to ethnicity
(Borch-Johnsen, 2013). Therefore, the percentage calculated on
a worldwide scale is only approximated and should be adjusted
based on the prevalent ethnicity in a national scope.
Despite any criteria discrepancy, the need to reduce the
prevalence of this disorder on a global scale becomes relevant.
Not only does the presence of MetS reduce life expectancy and
quality of life, but it also causes a financial burden derived from
high health costs (Rask-Madsen and Kahn, 2012). For this reason,
theWorld Health Organization (WHO) has as a priority to lower
the worldwide prevalence of non-communicable diseases like
CVD, DM2, and cancer, globally accounting for 63% of overall
deaths. One example of this intended approach is the taxing of
sweetened beverages.1
As aforementioned, MetS increases mortality and morbidity
and is associated with accelerated aging (Rask-Madsen and
Kahn, 2012). The aging process per se increases an individual’s
susceptibility to developing CVD or DM2. Interestingly, some
reports substantiate how MetS even in the absence of CVD or
DM2 also renders higher morbimortality (Borch-Johnsen, 2013).
The relevance of MetS in the modern industrialized society is
undeniable. Its staggering global prevalence and concomitantly
diminished quality of life rank this disorder as a major public
health concern.
Effects of Metabolic Syndrome on the
Nervous System
Over the years, the importance of MetS pertaining cardiovascular
risk and progression to DM2 has been carefully studied and
extensively divulged, for CVD is the leading cause of death
worldwide.2 However, research has been scarce with regard to the
effects of MetS on nervous tissue. In the recent years, the ever-
growing evidence suggests a correlation between Alzheimer’s
disease (AD) and other cognitive impairments, and MetS. These
results suggest that this syndrome does not only act as a risk
factor for CVD and DM2 but also contributes to the progression
toward AD (Kim and Feldman, 2015).
The nervous tissue has two vastly different cell populations:
neuronal and glial cells. Neurons are highly specialized cells that
propagate electrical stimulus in order to accomplish synaptic
transmission, while the glia (composed mainly by astrocytes,
oligodendrocytes, and microglia) is responsible for maintaining
the homeostasis in nervous tissue. The brain depends upon
glucose as its main source of energy, and a tight regulation
of glucose metabolism and ATP reserves are critical for brain
physiology (Mergenthaler et al., 2013; Brusco et al., 2014).
The aim of this review is:
1. First, to revise the pathophysiology of MetS and the
consequences of the intrinsically altered metabolism in the
nervous tissue.
2. To propose and explore different therapeutic approaches
aimed at reducing the compromised neuronal function and
neurodegenerative damage in MetS.
PATHOPHYSIOLOGY
Overview
It is imperative to acknowledge that MetS develops in susceptible
individuals bearing genetic factors and engaging in certain
epigenetic unhealthy habits like a sedentary lifestyle, excessive
1WHO Mid-term Programmatic and Financial Report for 2016–2017 including
audited financial statements for 2016 (WHA 70/40) (http://www.who.int/about/
finances-accountability/reports/en/).
2World Health Organization. The top 10 causes of death (Fact sheet) Updated
January 2017 http://www.who.int/mediacentre/factsheets/fs310/en/.
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consumption of high energy foods and drinks, smoking, and
many others. This complex disorder is characterized by a
sustained positive energy balance, which progressively breeds
a mild inflammatory environment due to the activation of
abnormal metabolic pathways (Kaur, 2014). Pivotal mechanisms
implied in MetS were described in this review: hyperglycemia,
insulin resistance (IR), inflammation and oxidative stress.
Patients with long-term MetS may be prone to develop
diabetic encephalopathy due to the diabetogenic milieu, entailing
moderate cognitive deficits, and both neurophysiological and
structural changes in the brain (Biessels et al., 2002). Passos
et al. demonstrated that the senescent cells had higher
reactive oxygen species (ROS) concentration, dysfunctional
mitochondria, more DNA double-strand breaks and shorter
telomeres. It was also shown that mitochondrial ROS enhanced
telomere-dependent senescence (Passos et al., 2007). Likewise,
some authors showed the link between telomere length and
metabolic disease suggesting increased cellular turnover and
therefore accelerated cell aging (Bonomini et al., 2011; Kong et al.,
2013). The increasing abdominal adiposity typical of the MetS
is accompanied by accelerated telomere attrition (Révész et al.,
2015).
Hyperglycemia
It is well-known that a high concentration of blood glucose
triggers diverse metabolic pathways. The most evident is the
tricarboxylic acid (TCA) cycle, due to an abundant amount of
substrate that in turn feeds the succeeding electron transport
chain (ETC). This energy surplus creates an imbalance of partially
reduced oxygen species favoring oxidant over antioxidant
compounds and resulting in oxidative stress (Kawahito et al.,
2009).
Another thoroughly described mechanism is the network
of glycation reactions bringing forth oxidative stress alongside
glucose toxicity (Kaneto et al., 1996). Advanced glycation end-
products (AGEs) are formed as a result of these non-enzymatic
reactions and promote inflammation by interacting with the
receptor of AGEs (RAGE) in cells of the immune system
(Gkogkolou and Böhm, 2012). The activation of the RAGE
triggers abundant intracellular signaling pathways including
kinases (e.g., MAP kinases, PI3 kinase), transcription factors as
the nuclear factor-κB (NFκB), and the activator protein-1. This
signaling cascade activates the further expression of cytokines,
chemokines, enzymes, and growth factors resulting in an overall
proinflammatory environment which leads to oxidative stress
(Medzhito and Horng, 2009).
Moreover, hyperglycemia reduces antioxidant levels and
increases the production of free radicals. The enzymes superoxide
dismutase (SOD) and catalase or glutathione peroxidase involved
in the antioxidant defense are down-regulated in the diabetic
brain (Suresh Kumar and Menon, 1993; Makar et al., 1995;
Miranda et al., 2007; Alvarez-Nölting et al., 2012). The possible
source of oxidative stress in brain injury, however, also includes
auto-oxidation of glucose, lipid peroxidation, and decreased
tissue concentrations of low molecular weight antioxidants like
reduced glutathione (GSH) (Reagan et al., 2000; Grillo et al.,
2003; Ulusu et al., 2003; Muriach et al., 2006). This alteration of
reduced glutathione levels may be related to an increased activity
of the polyol pathway as this leads to a depletion of the NADPH
required for enzymatic reduction of the oxidized glutathione
(Preet et al., 2005).
Overall, hyperglycemia creates a pro-oxidative environment
in live tissue involving various mechanisms. This condition
causes a detrimental effect on various cells and tissues, especially
those more vulnerable due to an insufficient antioxidant defense
like the pancreatic β-cells (Kaneto et al., 1999).
Insulin Resistance
Insulin is well-known for its role in the regulation of glucose
metabolism in the body. However, insulin has other roles in
the central nervous system (CNS) pertaining cognitive processes,
memory and synaptic plasticity (Zhao and Alkon, 2001).
Accordingly, either the deficiency of insulin or hyperinsulinemia
characteristic of type 1 or type 2 diabetes mellitus respectively
could be associated with degenerative events in the brain (Xu
et al., 2004).
Recent studies have suggested that the nervous system
is also capable of developing resistance to insulin. This
is possible even though neurons are not dependent on
insulin, they bear insulin receptors and are insulin-responsive
(Belfiore et al., 2009). Insulin receptors are expressed in brain
areas as the olfactory bulb, cerebral cortex, hippocampus,
hypothalamus and amygdala. Resistance to insulin in sensory
neurons affects the cellular response to growth factors, leading
to neurodegeneration, and neuropathy over time. In regard
to mitochondrial metabolism, insulin regulates the PI3K/Akt
(phosphatidylinositol 3-kinase/serine/threonine-specific Protein
Kinase B) intracellular transduction signaling pathway (Stiles,
2009; Cheng et al., 2010) which promotes survival and growth in
response to extracellular signals. This, in turn, affects neuronal
mitochondria, resulting in increased oxidative stress (Fisher-
Wellman and Neufer, 2012).
In addition, evidence has convincingly reported the
involvement of the mechanistic mammalian target of rapamycin
(mTOR) in cellular senescence. This pathway is activated by an
insulin dependent signal. The mTOR modulates cell growth and
cellular metabolism in response to growth factors, nutrients, and
cellular energy conditions. The loss of mTOR signaling disrupts
multiple responses in glucose metabolism, energy production,
mitochondrial function, and cell growth (Blagosklonny, 2013).
Inflammation
Inflammation is a biologically essential process which stands as
a common denominator in various pathological circumstances.
The inflammatory reaction is triggered in response to tissue
damage in an attempt to restore tissue homeostasis via repairing
mechanisms. In physiological conditions, the inflammatory
reaction is controlled and self-limited. However, when the fine
orchestrated regulation of these mechanisms is disrupted, the
uncontrolled inflammatory response usually ends in collateral
damage (Goldszmid and Trinchieri, 2012).
The amazingly complex immune system mediates the
response to unknown stimuli. When the inflammatory response
is unable to restore homeostasis, systemic, and cellular stress
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persists and physiological abnormalities develop (Okin and
Medzhitov, 2012). Diabetes is an example of a chronic
inflammatory disease (Pacher et al., 2007).
The production of ROS is a typical response to the stimulation
of immune system cells (Meier et al., 1989, 1990). Both, acute and
chronic inflammatory states have redox equilibrium alterations
due to the increased generation of oxidizing agents (Pacher
et al., 2007; Roberts et al., 2010; Li et al., 2013; Rochette et al.,
2013). Toll-like receptors (TLRs) activate NFκB, a regulator of
inflammation that is controlled by hundreds of genes and is also
a redox-sensitive nuclear factor, are at a key juncture between the
regulation of oxidative stress and inflammation.
Different experimental models from studies have described
that the activation of NFκB and proinflammatory cytokines is
associated to neuronal dysfunction, neuronal loss and impaired
cognitive function (Mattson and Camandola, 2001; Vincent et al.,
2002; Cai and Liu, 2012; Li et al., 2013). Activated NFκB can lead
to oxidative stress-induced cell dysfunction or death due to the
induction of cytotoxic products, which exacerbate inflammation
and promote apoptosis (Pahl, 1999; Morgan and Liu, 2011).
Overnutrition is considered as an independent environmental
factor which activates the innate immune system and triggers an
atypical form of inflammation leading to metabolic dysfunction
in the CNS (Cai and Liu, 2012). This inflammatory cascade
can also affect the hypothalamus and impair appetite control,
energy expenditure, carbohydrate and lipid metabolism, and
blood pressure homeostasis (Kahn and Flier, 2000; Lam et al.,
2005; Meister, 2007; Schenk et al., 2008; Zhang et al., 2008;
Shoelson and Goldfine, 2009). The molecular pathway involved
in this dysfunction is the activation of IKKβ/NFκB (Sonoda et al.,
2008; Cai, 2009; Lumeng and Saltiel, 2011).
The endoplasmic reticulum (ER) also plays a key role in the
metabolic imbalance caused by oxidative stress since it depends
on IKKβ/NFκB pathway activity (Zhang et al., 2008; Purkayastha
et al., 2011) and causes ROS accumulation (Cullinan and Diehl,
2006). Sustained exposure to high levels of blood glucose
promotes oxidative stress generating oxidative free radicals and
aberrant protein folding (Cullinan and Diehl, 2006).
Zhang et al. have reported an increase in the expression of
C/EBP (CCAAT/enhancer-binding protein) homologous protein
(CHOP) in the hippocampus of diabetic rats. This increase
suggests that CHOP-ER stress-mediated apoptosis could be
caused by hyperglycemia, impairing hippocampal synapses, and
promoting diabetic cognitive dysfunction (Zhang et al., 2013).
Oxidative Stress
As previously described, IR, inflammation, and hyperglycemia
all induce oxidative stress. The current concept of oxidative
stress conceived by Helmut and Jones is an “imbalance between
oxidants and antioxidants in favor of the oxidants, leading to
a disruption of redox signaling and control, and/or molecular
damage” (Sies and Jones, 2007). Free radicals are highly unstable
and reactive molecules which disrupt protein structure and
modify the physicochemical properties of membranes resulting
in organelles and cell damage. Some cardinal examples of
free radicals are the well-known ROS, which are byproducts
of the partial reduction of O2 (Figure 1). This fundamental
FIGURE 1 | End metabolic pathway of electron transport chain (ETC),
depicting the reduction of oxygen (O2) to water (H2O), and the formation of
reactive oxygen species (ROS) as a consequence of its partial reduction: O2
(Superoxide) H2O2 (hydrogen peroxide), OH (hydroxyl radical). Highlighted in
gray are shown the enzymes that catalyze the reactions (SOD:Superoxide
Dimutase).
reaction occurs in Complex IV of the ETC during physiological
respiration (Mitchell, 2012).
It is known that the appearance of oxygen in our world’s
atmosphere is directly correlated with the origin of the
powerhouse organelles in cells: the mitochondria (Poderoso,
2016). The mitochondria not only supply the cell with a greater
amount of ATP comparedwith othermetabolic pathways but also
play important roles in signaling apoptosis, thermoregulation,
and other vital processes. The adaptation to an aerobic lifestyle
benefited eukaryotic cells in many ways but also brought
complications. Unfortunately, the aerobic environment generates
ROS (Mitchell, 2012), and mitochondria are the main cellular
source of ROS. Metabolically active tissues as the liver, heart, and
brain are the major contributors of ROS to the body (Boveris and
Repetto, 2016).
The amount of ROS, normally produced in low
concentrations as byproducts of physiological processes
like respiration, is regulated by a variety of enzymes and other
molecules with antioxidant properties (Glutathione Peroxidase,
Glutathione Reductase, SOD, Vitamin C, Vitamin E, and the
β-carotenes) (Birben et al., 2012). When the redox homeostasis
is affected, ROS are overproduced exceeding the physiological
antioxidant capacity resulting in oxidative stress and causing
structural and conformational changes in mitochondrial
proteins, lipids, and nuclear material, thereby impairing their
function. Mitochondrial dysfunction in particular, eventually
leads to nerve cell damage. Since the nervous tissue is highly
metabolically active and critically dependent on energy supply, it
is unable to work properly in ATP shortcoming conditions (Bhat
et al., 2015).
In diabetic patients, aging may be associated with brain
dysfunction supported by the link between aging with cell
death and oxidative stress mediated by free radicals (Beckman
and Ames, 1998). In these pathological conditions, cellular
stress triggers oxidative mitochondrial damage, which in
turn may lead to apoptosis and/or necrosis (Merad-Boudia
et al., 1998). Apoptosis-induced oxidative stress has been
Frontiers in Neuroscience | www.frontiersin.org 4 April 2018 | Volume 12 | Article 196
Etchegoyen et al. Role of Antioxidants in the Context of Nervous Tissue
linked to neurogenesis inhibition (Cui et al., 2006). Alteration
in mitochondrial the ETC, ROS formation, dysfunction of
mitochondrial metabolism, and oxidative stress are recognized
as the main protagonists in complications related to diabetes
(Moreira et al., 2009).
Likewise, many studies have revealed that homocysteine,
associated with endothelial dysfunction, is responsible for the
release of hydrogen peroxide which causes cellular oxidative
stress and inflammation mediated by cell injury in vitro (Rozycka
et al., 2013). There is consensus that the activated microglia is
an important key mediator of proinflammatory and neurotoxic
factors involved in the progression of PD and AD. These
proinflammatory and neurotoxic factors include cytokines like
interleukin-6 (IL-6) and interleukin-1β (IL-1β), the tumor
necrosis factor-α (TNF-α) and ROS, consequently contributing
to oxidative stress (Bayarsaikhan et al., 2015).
Inexorably, altered metabolic homeostasis affecting multiple
metabolic pathways in MetS becomes the driving force toward
oxidative stress. The MetS should be regarded not only as a
predictor of CVD and DM2 but also as a silent threat to
cognitive performance and a risk for neurodegeneration (Kim
and Feldman, 2015). Timely assessment of risk for MetS and its
related conditions may be recommended.
Hypoxia
Metabolic syndrome (MetS) is associated with an increased risk
of cerebrovascular diseases, including cerebral ischemia (Aoqui
et al., 2014). The abnormal metabolic pathways involved in
MetS affect a broad variety of tissues, organs and systems,
including the cardiovascular system. Microvascular dysfunction
is particularly associated with MetS (Czernichow et al., 2010).
This is not surprising since DM2 progresses toward micro
and macrovascular dysfunction (Mitchell, 2012). Furthermore,
high blood pressure, increased pulse wave velocity suggesting
increased arterial stiffness, and low capillary density were found
in individuals with MetS (Greenstein et al., 2009). Vascular
degeneration brings forth a flawed circulation, which in turn
leads to hypoxia in target organs like the brain.
There is ever-growing evidence for obesity associated with
changes in perivascular adipose tissue, which gives forth an
altered vasoactive tone of the microvasculature (Obadia et al.,
2017). Some key factors that may play a crucial role regarding
these vascular modifications are cardinal molecules that are
increased substantially in MetS: free fatty acids and adipokines
(TNF-α) (Greenstein et al., 2009). Additionally, not only do
individuals with MetS have a higher likelihood of microvascular
dysfunction, but they are also more susceptible to damage during
ischemia-reperfusion events (Aoqui et al., 2014).
The cluster of these elements poses important risk factors
toward producing hypoxia in tissues that have a strict oxygen
supply requirement, such as nervous tissue. The neurovascular
unit (composed of neurons, astrocytes and endothelial cells) is
the structure in charge of maintaining the brain’s homeostasis
(Gorelick et al., 2011). Studies show that the dysfunction of this
unit plays a crucial role regarding the onset of neurodegenerative
conditions, such as AD (Zlokovic, 2008; Grammas, 2011;
Marchesi, 2014). In fact, reports have associated stroke patients
with progression toward AD, where hypoxic/ischemic injury
promotes the formation of β-amyloid plaque (Guglielmotto et al.,
2009).
NEUROPROTECTION
Neuroprotection encompasses the therapeutic actions to prevent
or limit the progression of neuronal degeneration (Orsini et al.,
2016). A vast array of noxious stimuli can trigger damage in
nervous tissue. Among these, altered metabolic pathways and
hypoxia are themain focus of this review (Marcano Torres, 2004).
The therapeutic approaches regarding neuroprotection
discussed in this review comprise three instances: lifestyle habits,
MetS symptoms medication (hypertension, hyperglycemia, and
dyslipidemia), and antioxidant treatment.
Lifestyle: Nutritional Habits and Exercise
A fundamental cornerstone of neuroprotection in the context of
MetS concerns striving toward physical wellness obtained by a
balanced diet and exercise through a multidisciplinary approach.
This item alone can revert hypertension, hyperglycemia, and
dyslipidemia, without the need to implement medication
(Pitsavos et al., 2006).
Nutritional Habits
Reducing daily calorie intake and adopting a dietary style
like the Mediterranean diet or the Dietary Approaches to
Stop Hypertension (DASH) is advisable. While both dietary
strategies improve the patient biochemical profile, the DASH
was more beneficial in normalizing blood pressure (Kaur, 2014).
The Adult Treatment Panel III (ATP III) recommends a diet
for cholesterol management containing 25–35% of total fat
to reduce the low density-cholesterol (LDL-C) fraction level
(National Cholesterol Education Program, 2001). We have
reported that chronic consumption of cola beverages impairs
metabolic homeostasis increasing glycemia, cholesterolemia,
triglyceridemia, and systolic blood pressure. Systolic blood
pressure and most of the biochemical parameters normalize after
switching cola beverages to tap water over a sustained washout
period. However, hypertriglyceridemia is resistant and persists
long after discontinuing cola consumption (Milei et al., 2011;
Otero-Losada et al., 2014, 2015, 2016a).
Exercise
Health professionals should indicate exercise programs, such
as 30min or more of moderate-intensity physical activity and
preferably all days of the week (Thompson et al., 2003).
Continuing evidence from our research reports a beneficial
effect of exercise on pancreatic morphology in long-term cola-
drinking rats. These results support the by now accepted positive
correlation between exercise and physical wellness (Otero-
Losada et al., 2016b).
However, when modifying lifestyle habits does not revert
pathological values, it is time to take the next level of action
including a pharmacological therapeutic approach. Nevertheless,
physical wellness should always compliment the medication.
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Medication Targeted Toward Mets Cardinal
Symptoms
The cardinal symptoms of MetS with indicated pharmacological
treatment are hypertension, dyslipidemia, and hyperglycemia.
Hypertension
At present, a vast array of antihypertensive drugs is available
(Gupta and Guptha, 2010). However, the election of a specific
pharmacological association should consider a holistic view of
each patient, always bearing in mind the individual idiosyncrasy
and any other relevant factor (Gutiérrez, 2001). There is a certain
structure regarding the course of drug administration that is
validated by clinical trials in hypertensive patients. Treatment
should initiate with a mono-drug treatment and only escalate
indicating additional drugs with different mechanism of action
in patients that do not normalize their blood pressure (Rivas-
Chávez et al., 2007).
The first line drugs in pharmacological therapy3:
• Angiotensin Converting Enzyme (ACE)
inhibitors/Angiotensin II Receptor Blockers (ARBs) which
inhibit receptor binding to angiotensin II.
• Dihydropyridine Calcium Channel Blockers (CCBs) which
inhibit Ca2+ influx into smooth muscle cells in vessels.
• Thiazide Diuretics which inhibit the reabsorption of Na+ and
Cl− in the distal tubules of the nephron.
The second line drugs in pharmacological therapy are
administered to patients with risk factors or developing side
effects from the first-line drugs (Gutiérrez, 2001; Sweitzer, 2003;
De Luis Román et al., 2008).
Dyslipidemia
The pharmacological approach to normalize blood lipids
comprises a variety of drugs indicated according to the patient’s
specific abnormality (Tonkin and Byrnes, 2014). In patients
with MetS, the pharmacological goal is to decrease the LDL-C
fraction and triglycerides, and increase the HDL-C fraction in
blood. The classical first-line drugs involve statins, fibrates and
inhibitors of cholesterol absorption while thiazolidinediones,
GLP-1 agonists, and DPP-4 inhibitors seem to be promising
therapeutic alternatives (Binesh Marvasti and Adeli, 2010).
Statins decrease LDL-C level acting as inhibitors of the 3-
hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase,
which is the key enzyme in cholesterol endogenous synthesis
(Baigent et al., 2010). Most frequent adverse side effects of long-
term treatment with statins are hepatotoxicity and myopathy
(Pescio, 2001).
Ezetimibe, the standard cholesterol absorption inhibitor,
impairs cholesterol luminal transport in the small intestine by the
enterocyte (Tonkin and Byrnes, 2014). This drug lowers blood
level of LDL-C and its effect increases when associated with a
statin (Binesh Marvasti and Adeli, 2010).
Another drugs used in MetS are the fibrates, which
activate peroxisome proliferator-activated receptors (PPARs)
3National Institute for Health and Clinical Excellence Hypertension (CG127).
http://www.nice.org.uk/guidance/cg127. Accessed October 10, 2017.
eventually improving lipid and carbohydrate metabolism. The
fibrates are very effective at lowering blood triglycerides,
reducing LDL-C, and increasing HDL-C as well (Staels et al.,
1998). The thiazolidinediones are insulin-sensitizing drugs (i.e.,
rosiglitazone) that also act as PPARs stimulators and are used to
normalize glycemia (Krentz et al., 2008).
The incretins, typically, the glucagon-like peptide-1 (GLP-1)
and the glucose-dependent insulinotropic peptide (GIP), are gut
hormones secreted by the enteroendocrine cells within minutes
after ingestion and they stimulate insulin secretion after eating
(Ahrén, 2003). Their use is promising in patients with DM2
(Meier and Nauck, 2006). The dipeptidyl peptidase-4 (DPP-4) is
the enzyme responsible for lowering the level of incretin in blood
to the basal level. Hence, the administration of DPP-4 inhibitors
increases insulinemia (Kendall et al., 2006).
Hyperglycemia
The leading non-insulin antidiabetic pharmacological
groups are the insulin-sensitizing drugs (biguanides and
thiazolidinediones), insulin secretagogues (sulfonylureas,
meglitinides, and incretins), and starch blockers (α-glucosidase
inhibitors) (Rockville, 2007; Zárate et al., 2010; Powers and
D’Alessio, 2012). The preferred drugs in MetS are those that
do not have a direct effect on pancreatic β-cells, such as
biguanides (metformin), thiazolidinediones (rosiglitazone), and
α-glucosidase inhibitors (acarbose) (Mamedov and Shishkova,
2007). Themain advantage of these euglycemic agents is avoiding
hypoglycemia as a side effect (Vlckova et al., 2009).
Data describing clinical evidence concerning anti-MetS
treatment and its effect on cognitive impairment is summarized
in Table 1.
Medication Targeting Oxidative Stress
As described in this review, the common denominator of various
pathological pathways is an overall pro-oxidative status. The use
of diverse antioxidative strategies has been evaluated to mitigate
oxidative stress, mainly in diabetic neuropathy (Spychalowicz
et al., 2012).
Antioxidant Drugs
Among the wide variety of antioxidant compounds, the following
have been thoroughly studied:
• Vitamins A, C, and E
• Flavonoids
• Alpha-lipoic acid (ALA)
• Lutein and docosahexaenoic acid (DHA)
Other antioxidants have shown neuroprotection as well. Such
is the case of the amino acids Taurine, acetyl L-carnitine,
N-acetylcysteine (Negre-Salvayre et al., 2008; Shakher and
Stevens, 2011; Wang et al., 2011; Hosseini and Abdollahi, 2013),
synthetic ROS scavengers like tempol and SOD mimetics (De
Silva and Miller, 2016), and resveratrol which decreases the
activity of NF-κβ. Also, TNF-α, IL-6, and Cox-2, angiopoietin-
1 which protects against brain stroke (Nguyen et al., 2012), the
anti-inflammatory cytokines IL-10 and IL-8 (Shukla et al., 2017),
mitochondrial antioxidants as the coenzyme Q10 (Chew and
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TABLE 1 | Effect of anti-MetS treatment on cognitive processes, and brain circulation and metabolism in clinical trials.
Symptoms Drug n Sample Characteristics Study Time Results References
HYPERTENSION ACE inhibitor 616 Mild/Moderate AD 4-year prospective Mini-Mental State Examination
(MMSE) decline between control
and placebo
Soto et al., 2013
CCB 18,423 Elderly hypertensive patients
older than 60 years
12-year prospective CCB use significantly reduced
the risk of total dementia,
Alzheimer’s dementia, and
vascular dementia
Hwang et al., 2016
Thiazide Diuretics 3,417 Elderly hypertensive
population with AD
7-year prospective Use of any anti-hypertensive
medication was associated with
lower incidence of AD. Thiazides
were associated with the
greatest reduction of AD risk
Chuang et al., 2014
HYPERGLYCEMIA Metformin (Biguanides) 20 Mild cognitive impairment or
mild dementia due to AD
16-week prospective Metformin was associated with
improved executive functioning,
and trends suggested
improvement in learning/memory
and attention
Koenig et al., 2017
Pioglitazone (TZD) 42 Mild AD with type II
Diabetes Mellitus
6-month prospective The pioglitazone group improved
cognition and regional cerebral
blood flow in the parietal lobe
Sato et al., 2011
Rosiglitazone (TZD) 30 Mild AD or amnestic mild
cognitive impairment
6-month prospective Relative to the placebo, better
delayed recall, and selective
attention
Watson et al., 2005
GLP-1 agonists 9 Healthy, Caucasian males
with a mean age of 22 years
old
4-week prospective Ensures less fluctuation of brain
glucose levels
Gejl et al., 2012
DYSLIPIDEMIA Simvastatin 46 45–64 year old participants
with normal cognition,
grouped by high or normal
cholesterol
12-month prospective Reduction of p-tau in CSF seen
in patients who had high initial
baseline LDL cholesterol
Li et al., 2017
ACE, angiotensin converting enzyme; CCB, calcium channel blockers; TZD, thiazolidinedione; CSF, cerebral-spinal fluid; LDL, low-density lipoprotein.
Watts, 2004), and uncoupler proteins (UCPs) (Harper et al.,
2001; Green et al., 2004) have neuroprotective effects. Some of
these drugs as tempol and the anti-inflammatory cytokines have
improved the response to hypoxic events reducing the spread of
microhemorrhages (Han et al., 2015; Shukla et al., 2017).
Vitamins A, C, and E are dietary antioxidants capable of
directly reducing free radicals and participating in the recycling
of antioxidant cofactors (Maritim et al., 2003). The antioxidant
vitamins also boost the immune system, preserve DNA structure
avoiding oxidative damage, and alleviate diabetic neuropathy
symptomatology, all linked with oxidative stress reduction
(Niedowicz and Daleke, 2005; Rahman et al., 2006; Valko et al.,
2007; Salah et al., 2010).
Several subclasses of flavonoids are free radical scavengers
found in plants (Nijveldt et al., 2001; Arts and Hollman,
2005; Nettleton et al., 2006; Lukacˇínová et al., 2008). Some
examples are: proanthocyanidin, luteolin, hesperidin, fisetin,
epigallocatechin-gallate, rutin, and quercetin have been shown
to possess antioxidant activities which protect against diabetic
neuropathy (Al-Enazi, 2003; Cui et al., 2008; Ibrahim, 2008;
Maher et al., 2011; Wang et al., 2011; Baluchnejadmojarad and
Roghani, 2012; Ferreira et al., 2013).
Alpha-lipoic acid (ALA), an amphiphile antioxidant molecule,
has proved to be likely the most successful antioxidant in clinical
trials (Vallianou et al., 2009). Both ALA and its active metabolite
(DHLA), act at different levels as antioxidants; they are free
radical scavengers, inhibit the hexosamine and AGEs pathways,
and are also involved in the intracellular regeneration of ascorbic
acid (vitamin C), alpha-tocopherol (vitamin E), and oxidized
glutathione (GSSG) (Packer et al., 2001; Du et al., 2008; Vallianou
et al., 2009). Many experimental models support the beneficial
effects of ALA in diabetic neuropathy (Nagamatsu et al., 1995;
Evans et al., 2002; Ametov et al., 2003; Baydas et al., 2004; Ziegler
et al., 2004, 2006, 2011; Tankova et al., 2005; Du et al., 2008;
Huang and Gitelman, 2008; Gianturco et al., 2009; Vallianou
et al., 2009).
The advantageous treatment with lutein and DHA in the brain
of diabetic animals, and the way that these substances were able
to mitigate the intrinsically oxidative environment in diabetes
has also been studied (Muriach et al., 2006; Arnal et al., 2010).
Moreover, treatment with DHA improved memory and learning
skills in patients with Alzheimer’s disease, related to a decrease in
the concentration of lipid peroxide and ROS (Hashimoto et al.,
2005).
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Mitigating Oxidative Stress Pathways
Diverse research projects have studied the downstream sequence
of reactions and biochemical avenues undergoing oxidative stress
as possible targets for the treatment of oxidative neuropathy. For
the purpose of this review, we will focus on Aldose Reductase
Inhibitors (ARIs), PKC Inhibitors, and Anti-AGE Agents.
Aldose Reductase Inhibitors (ARIs)
The aldose reductase enzyme participates in the synthesis
of sorbitol and fructose. The ARIs decrease the amount of
glucose entered into the polyol pathway avoiding neuronal
accumulation of sorbitol and fructose. Based on the positive effect
of ARIs administration in neuropathies caused by oxidative stress
(Hotta et al., 1996; Yagihashi et al., 2001), clinical trials were
conducted to test the effects of Fidarestat (SNK-860) (Hotta et al.,
2001), Epalrestat (Hotta et al., 2006; Ramirez and Borja, 2008;
Sharma and Sharma, 2008), and Ranirestat (AS-3201) (Bril and
Buchanan, 2004; Bril et al., 2009). To date, only Epalrestat has
a license in Japan while the other two were removed from the
market (Casellini and Vinik, 2006; Kawai et al., 2010; Schemmel
et al., 2010).
Protein Kinase C (PKC) Inhibitors
The PKC enzyme participates in the activation of key regulatory
proteins responsible for the synthesis of neurotransmitters, and
it is essential for nerve impulse conduction. Different studies
have shown that PKC participates in alleviating neuropathic pain
(Chattopadhyay et al., 2008; Norcini et al., 2009). The specific
PKC-1b inhibitor Ruboxistaurin improved axonal velocity and
endoneurial blood flow in diabetic rats (Nakamura et al., 1999).
In clinical trials, Ruboxistaurin slowed down the progression
of diabetic neuropathy but was not effective in suppressing the
neuropathic symptomatology (Vinik et al., 2005).
Anti-advanced glycation end products (AGEs) Agents
Some drugs may prevent or inhibit AGEs formation and
accumulation. The anti-AGEs drug’s family is also responsible
for disrupting the interaction between AGEs and AGEs
receptors (RAGEs), which would otherwise magnify oxidative
damage. Some examples of these agents are Benfotiamine,
Aminoguanidine, Aspirin, and Rapamycin (Haupt et al., 2005;
Edwards et al., 2008).
• Benfotiamine increases the activity of the Transketolase
enzyme which is responsible for directing AGE substrates
to the phosphate pentose pathway, consequently reducing
hyperglycemic damage. Benfotiamine also inhibits the increase
in UDP-N-acetylglucosamine (UDP-GlcNAc), which in turn
limits the substrate’s capacity to enter the hexosamine
pathway, reducing AGEs production (Stirban et al., 2007;
Balakumar et al., 2010).
• Aminoguanidine reacts with 3-deoxyglucosone, an AGE
precursor, inactivating the reactive carbonyl residues essential
to enzymatic activity, and preventing AGEs formation. Studies
on this compound, however, have been discontinued due to its
toxicity (Yan et al., 2008).
• In Vitro studies have shown that aspirin inhibits the
production of pentosidine (an AGE) by accepting free radicals
and ionic chelants in the presence of collagen (Urios et al.,
2007).
• Ding et al. studied the activity of Rapamycin, an inhibitor
of the proapoptotic mTOR-p53-Bax pathway, showing that
Rapamycin injection 4 h after causing an injury, improved
functional recovery. Recovery consisted of a reduction in
microglial and macrophage activation, a decreased rate of
apoptosis, and an improved neurobehavioral function (Ding
et al., 2015).
Our Research
As already mentioned, one of our research lines investigates the
effects of chronic cola beverages consumption in murine models.
Clear evidence of beneficial effects of a wash-out period (diet)
and exercise have been reported (Milei et al., 2011; Otero-Losada
et al., 2014, 2015, 2016a,b).
Another study conducted in our institution included elderly
patients of both sexes that attended periodical routine check-
ups, with the purpose of evaluating the effectiveness of short-
term antioxidant supplementation. The outcome of our study
confirmed that antioxidant supplementation improved plasma
biochemistry as a result of changes in oxidative metabolism,
typically in those patients having low basal endogenous
antioxidants concentration in plasma. Based on these results, we
recommended measuring the basal level of plasma antioxidants
before starting any supplementation with antioxidants in elderly
cardiovascular patients, a particularly vulnerable population with
special precautions to be endorsed. Not only adverse effects
were not reported during the course of our study, but subjective
observations as “feeling more vital” or experiencing a state of
“general well-being” were declared (Otero-Losada et al., 2013).
Using an experimental model, we assessed the therapeutic
benefits of medical grade ozone, a mixture of 0.05–5% of pure
O3 and 95–99.5% of pure O2 according to the pharmaceutical
legislation. We reported promising effects of medical ozone
auto-hemotransfusion on the cardiovascular system injury.
Pretreatment with ozone auto-hemotransfusion decreased
neointimal proliferation and induced reendothelialization
following a metal stent insertion (Barone et al., 2016). The
protective mechanism whereby ozone reduces restenosis appears
to involve the ozone well-described oxidative preconditioning
upregulating the antioxidant enzymes, and improving the
antioxidant response to an eventual injury (Barone et al., 2016).
Cognitive impairment or skills were not assessed in these
experimental models. However, the promising outcome
encourages pursuing further study of cognitive abilities as well.
Clinical Relevance Regarding
Neurodegenerative Diseases
Among neurodegenerative disorders, AD has been extensively
studied regarding cognitive impairment in the setting of MetS
(Hashimoto et al., 2005; Moreira et al., 2009; Mayeux and Stern,
2012; Zhang et al., 2013; Jayaraman and Pike, 2014; Kleinridders
et al., 2014; Kim and Feldman, 2015). This tendency is reasonable
since there is genetic evidence showing the apolipoprotein E
(ApoE) as a common gene which links dementia, MetS, and
diabetes (Zhang et al., 2017). Moreover, it is also crucial to bear
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in mind the extent of hardships that come hand in hand with AD
(i.e., long-term functional dependence of the affected patients,
the cost of living, quality of life, etc.), making this disorder
an important public health issue (Agüero-Torres et al., 1998;
Geldmacher et al., 2006). One of the challenges for public health
is to identify risk factors, and the MetS is definitely a prevailing
one. The compelling association between altered metabolic states
and dementia may provide insight on a therapeutic approach
that can delay cognitive impairment, targeting the underlying
pathophysiological pathways of MetS (de la Monte, 2017).
Staggering evidence demonstrates that AD pathogenesis
is strongly associated with oxidative stress, inflammation,
and insulin, glucose, and lipid dysregulation; all of these
pathological pathways are present in MetS and other altered
metabolic states (Rojas-Gutierrez et al., 2017). Consequently,
a vast number of studies have shown anti-MetS treatments
to improve diverse aspects of cognition in patients with AD
(Chen et al., 2016; de la Monte, 2017; Rojas-Gutierrez et al.,
2017). An example of said treatments include drugs like
gut incretins, thiazolidinediones, and metformin, which show
promising results regarding cognitive impairment in animal
and clinical trials, improving the effects of insulin via different
mechanisms (Chen et al., 2016). Table 1 summarizes some data
observed in clinical trials pertinent to anti-MetS treatment.
Furthermore, studies on anti-oxidative treatment in patients
with AD also present supportive results. For instance, flavonoids
scavenge free radicals and have shown to promote neuronal
survival in the hippocampus (Venkatesan et al., 2015). Another
promising antioxidant treatment involves the administration
of the synthetic S-acyl derivative of thiamine (vitamin B1)
Benfotiamine in clinical trials reporting a long-term cognitive
improvement, suggesting a possible disease-modifying therapy
(Pan et al., 2016). Also, both AD and IR led to deregulation
of the mTOR pathway, and treatment with the mTOR inhibitor
Rapamycin resulted in learning andmemory improvement in AD
(Vieira et al., 2017).
Ultimately, the emerging global epidemic of
neurodegenerative disorders as the world population ages
is of great concern (Brookmeyer et al., 2007). Any insight
regarding neuroprotection and delaying the onset of cognitive
impairments is of utmost value. The ever-growing evidence
of the association between AD and MetS not only allows a
deeper comprehension of the pathogenic circuits but also lays
the foundations for developing new therapeutic approaches
aimed at normalizing both shared and intertwined pathological
pathways underlying the two conditions (Agüero-Torres et al.,
1998; Geldmacher et al., 2006; Venkatesan et al., 2015; Chen
et al., 2016; Pan et al., 2016; de la Monte, 2017; Rojas-Gutierrez
et al., 2017; Vieira et al., 2017; Zhang et al., 2017).
CONCLUSION
Metabolic Syndrome (MetS) is an ever-growing disorder affecting
up to 25% of the population in industrialized countries increasing
morbimortality. Given these proportions, it has become an
epidemic of public health concern. Increasing evidence shows
that MetS is a risk factor for neurological disorders, beyond its
classical association with CVD and DM2.
Hyperglycemia, IR, inflammation, oxidative stress, and
hypoxia are key pathological pathways associated with MetS.
It is a question of time until this cluster of conditions results
in tissue damage in target organs such as the brain and the
microvasculature that irrigates the nervous system. Oxidative
stress and hypoxia are actually linked to neurological diseases like
Alzheimer’s and Parkinson’s (Kim and Feldman, 2015).
The therapeutic strategies suggested in this review entail
multidisciplinary interventions involving different pathological
pathways in concert. These include improving lifestyle and daily
habits (diet and exercise), treating the cardinal symptoms of
MetS, and reducing the pro-oxidative load in affected patients.
Antioxidant therapy is not routinely used in MetS, although
extensive research relative to its benefits in diabetic neuropathy is
available. Hence, we consider that diminishing the pro-oxidative
status in patients with MetS may play a critical role in reducing
brain hypoxic damage and behavioral deficits.
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